Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension
Pulnovo Medical raised $100 million with Medtronic backing. Read what it means for PADN, pulmonary hypertension, heart failure, and device markets.
Medical Devices & Diagnostics
Pharma & Biotech
Can Merck expand WINREVAIR beyond pulmonary arterial hypertension after CADENCE data?
Can Merck turn WINREVAIR’s CADENCE data into a new treatment path in CpcPH-HFpEF? Read the full analysis of what changes next.
Pharma & Biotech
Why WINREVAIR’s Phase 2 data matters beyond pulmonary arterial hypertension
CADENCE trial data shows sotatercept’s promise in HFpEF-linked pulmonary hypertension. Find out what this means for treatment and regulation.
Medical Devices & Diagnostics
What Anumana’s FDA-cleared pulmonary hypertension algorithm means for cardiovascular AI
Anumana won FDA clearance for an ECG-AI pulmonary hypertension tool. Read what it changes for diagnosis, workflow adoption, and cardiovascular AI strategy.
Medical Devices & Diagnostics
CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data
CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women's heart care. Read more.
Pharma & Biotech
United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Pharma & Biotech
GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy
GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.